# US 8,277,819 B2 · Norovirus particle for use as an antiviral or vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,819 B2
- Document ID: US8277819B2
- Status: Granted
- Kind: B2
- Application number: 11/917,862
- Filed: 2006-06-15
- Published: 2009-11-12
- Granted: 2012-10-02
- Earliest claimed: 2005-06-16
- Assignees: Children's Hospital Medical Center
- Inventors: Xi Jiang; Ming Tan
- Web page: https://patentgrep.com/patent/US8277819B2

## CPC

- G01N 33/56983: {Viruses}
- C07K 14/005: from viruses
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/5258: {Virus-like particles}
- C12N 2770/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/16023: Virus like particles [VLP]
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Norovirus capsid protein monomers having only the P domain, and not the hinge or S domain, can assemble spontaneously into an icosahedral form herein called the P-particle. Factors affecting the formation and stability of the P-particle, as well as providing methods for diagnosing and treating Norovirus-infected individuals and creating a vaccine for prevention of Norovirus infection are presented.

## Claims

### Claim 1

A composition for inducing an immune response in an individual against Norovirus, the composition comprising a therapeutic amount of a P-particle in a suitable sterile, nontoxic physiological medium, wherein the P-particle comprises Norovirus capsid P domain monomers selected from the group consisting of SEQ ID NO:2, a P protein, a P protein without a hinge, a P protein with a hinge and a cysteine linked to the end of a P1 subdomain of the P protein, and mixtures thereof.

### Claim 2 (depends on 1)

The vaccine of claim 1, wherein the P-particle comprises capsid P domain monomers from the Norovirus strain VA387.

### Claim 3

A method of inducing an immune response in an individual against Norovirus, the method comprising the step of orally or parenterally administering to an individual at least one immunologically effective dose of a composition comprising an isolated P-particle, the P-particle comprising a P protein from a Norovirus strain recombinantly expressed or synthesized from a cDNA comprising a fragment of the cDNA sequence of the capsid protein of the Norovirus strain, and a pharmaceutical carrier, wherein the dose is effective in inducing the immune response in the individual.

### Claim 4 (depends on 3)

The method of claim 3, wherein the fragment is SEQ ID NO:2.

### Claim 5 (depends on 3)

The method of claim 3, wherein the protein comprises a cysteine linked to the end of a P1 subdomain of the P protein, and wherein the isolated P-particle comprises a plurality of P-Particles which have been purified.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cysteine linked to the end of the P1 subdomain of the protein, results in the P-particle being more stable than the original P-particle without the cysteine linkage.

### Claim 7

An isolated P-particle comprising capsid P domain monomers from a Norovirus strain.

### Claim 8 (depends on 7)

The isolated P-particle of claim 7, wherein the isolated P-particle comprises a plurality of capsid P domain monomers, the capsid P domain monomers selected from the group consisting of P protein without a hinge, and P protein with a hinge and a cysteine linked to the end of a P1 subdomain of the P protein, and mixtures thereof.

### Claim 9 (depends on 8)

The isolated P-particles of claim 8, wherein the P protein without a hinge further comprises a cysteine linked to the end of the P1 subdomain of the P protein.

### Claim 10 (depends on 9)

The isolated P-particles of claim 9, wherein the a cysteine linked to the end of a P1 subdomain of the P protein, resulst in the P-particles being more stable than the original P-particles without the cysteine modification.

### Claim 11 (depends on 7)

The isolated P-particle of claim 7, wherein the Norovirus strain is selected from the group consisting of NV, MOH, and VA 387.

### Claim 12 (depends on 7)

The isolated P-particle of claim 7, wherein the Norovirus strain is selected from the group consisting of NV, MOH, Mexico, VA207, VA387, 02-1419, C59, VA115, Hawaii, Snow Mountain, Hillington, Toronto, Leeds, Amsterdam, Idaho Falls, Lordsdale, Grimsby, Southampton, Desert Shield, Birmingham, and White Rivercap.

### Claim 13 (depends on 7)

The isolated P-particle of claim 7, wherein the P-particle is a purified recombinant P-particle in the shape of an icosahedron, the icosahedron comprised of 24 monomer units of SEQ ID NO:2.

### Claim 14 (depends on 7)

The isolated P-particle of claim 7, wherein the P-particle comprises capsid P domain monomers from the Norovirus strain VA387.

### Claim 15 (depends on 1)

The composition according to claim 1, wherein the P-particle has increased receptor binding activity with human histo-blood group antigens as compared to a P dimer particle.

### Claim 16 (depends on 1)

The composition according to claim 1, wherein the P-particle comprises a dimer of the P protein.

### Claim 17 (depends on 2)

The composition according to claim 2, wherein the P protein without a hinge further comprises a cysteine linked to the end of the P1 subdomain of the P protein.

### Claim 18 (depends on 3)

The method according to claim 3, wherein the Norovirus strain is VA387.
